Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06388421 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 67 → 71 locationsv21
  2. Trial sites expanded: 62 → 67 locationsv20
  3. Site contacts updated at 1 of 62 sitesv19
  4. Study sites: 61 to 62v18
  5. Enrollment reduced: 1000 → 900 participants Trial arms changed: 3 → 4 · Study sites: 59 to 61 · Eligibility criteria expanded, about 121 words · 2 morev17 Show 5 more changesShow less
    • Trial arms changed: 3 → 4
    • Study sites: 59 to 61
    • Eligibility criteria expanded, about 121 words
    • Primary endpoint revised
    • Study description expanded, about 43 words

    See this version in full on ClinicalTrials.gov ↗

Show 15 earlier versionsHide 15 earlier versions
  1. Study sites: 45 to 59v16
  2. Study sites: 34 to 45v15
  3. Study sites: 22 to 34v14
  4. Study sites: 16 to 22v13
  5. Study sites: 11 to 16v12
  6. Study sites: 10 to 11v11
  7. Study sites: 9 to 10v10
  8. Study sites: 8 to 9v9
  9. Study sites: 6 to 8v8
  10. Study sites: 5 to 6v7
  11. Study sites: 4 to 5v6
  12. Study sites: 2 to 4 Start date changed from estimate of Jan 31, 2025 to Jan 23, 2025v5 Show 1 more changeShow less
    • Start date changed from estimate of Jan 31, 2025 to Jan 23, 2025
  13. Trial status: Not Yet Recruiting to Recruiting Start date: Sep 1, 2024 to Jan 31, 2025 · Study sites: 0 to 2v4 Show 2 more changesShow less
    • Start date: Sep 1, 2024 to Jan 31, 2025
    • Study sites: 0 to 2
  14. Start date: Aug 1, 2024 to Sep 1, 2024 Primary completion date: Aug 1, 2030 to Sep 1, 2030v3 Show 1 more changeShow less
    • Primary completion date: Aug 1, 2030 to Sep 1, 2030
  15. Study description shortened, about 5 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
United Therapeutics
13 trials monitored
See 2 trials at risk
Hypertension
1,795 trials monitored
See 85 trials at risk
This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).
Trial Details
NCT Number NCT06388421
Lead Sponsor United Therapeutics
Conditions Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov